We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Synovus (SNV) Unveils Share-Buyback Plan: Worth a Look?
Read MoreHide Full Article
Synovus Financial (SNV - Free Report) continues to reward its shareholders through dividend hikes or additional share repurchases. The company’s board of directors recently increased the share-buyback plan with authorization by $325 million to repurchase shares worth $725 million for 2019. Notably, after repurchase of about $325 million worth common stock under the existing share-buyback program, Synovus had remaining $400 million of common stock available for repurchase during the ongoing year.
Such repurchases may be made in the open market, in privately negotiated transactions, or otherwise. The repurchase authorization does not obligate the company to repurchase any dollar amount or number of securities and may be suspended or discontinued any time.
Funding of the share repurchase is likely to include cash on hand, future cash flow from operations, borrowings and financings.
Notably, Synovus has also been paying quarterly dividends, along with regular hikes. Since December 2016, the company has raised its dividend thrice. Its dividend was last hiked this March by 20% to 30 cents from 25 cents per share.
Synovus has rallied 2.2%, year to date, compared with the industry’s growth of 11.6%. Currently, the stock carries a Zacks Rank #3 (Hold).
With strong liquidity and balance-sheet position, we believe Synovus will continue to reward its shareholders, moving ahead. So, keeping this in mind, is the company worth considering? Let’s dig deeper into its financials and fundamental strengths.
Value Score: Synovus currently has a Value Score of B. The Value Score condenses all valuation metrics into one actionable score that helps investors steer clear of “value traps” and identify stocks that are truly trading at a discount.
Earnings Strength: Synovus has an expected earnings growth rate of 8%, for the coming three to five years. With its earnings momentum, the earnings growth rate is anticipated to be around 10.7% for the current year and 2.3% for 2020. Furthermore, the company recorded an average positive earnings surprise of 3.64%, over the trailing four quarters.
Revenue Growth: Synovus is focused on its organic growth strategy. Loans witnessed a CAGR of 5.3% for the last five years (2014-2018). In addition, net interest income (NII) witnessed a CAGR of 8.8% during the same time frame, partly driven by the acquisitions completed during this period. The increasing trend continued in first-quarter 2019 as well. Further, the company’s projected sales growth (F1/F0) of 35.5% (against nil industry average) indicates continued improvement in revenues.
Superior Return on Equity (ROE): Synovus’ ROE of 15.58%, as compared with the industry average of 9.93%, highlights the company’s commendable position over its peers.
Stocks to Consider
First Business Financial Services, Inc. (FBIZ - Free Report) has been witnessing upward estimate revisions, for the past 60 days. Moreover, this Zacks #1 (Strong Buy) Ranked stock has rallied more than 20%, year to date. You can see the complete list of today’s Zacks #1 Rank stocks here.
Franklin Resources, Inc. (BEN - Free Report) has been witnessing upward estimate revisions, for the past 60 days. Also, the company’s shares have gained nearly 10.8% year to date. At present, it carries a Zacks Rank of 2 (Buy).
1st Source Corporation (SRCE - Free Report) has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has jumped around 10.5% year to date. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Synovus (SNV) Unveils Share-Buyback Plan: Worth a Look?
Synovus Financial (SNV - Free Report) continues to reward its shareholders through dividend hikes or additional share repurchases. The company’s board of directors recently increased the share-buyback plan with authorization by $325 million to repurchase shares worth $725 million for 2019. Notably, after repurchase of about $325 million worth common stock under the existing share-buyback program, Synovus had remaining $400 million of common stock available for repurchase during the ongoing year.
Such repurchases may be made in the open market, in privately negotiated transactions, or otherwise. The repurchase authorization does not obligate the company to repurchase any dollar amount or number of securities and may be suspended or discontinued any time.
Funding of the share repurchase is likely to include cash on hand, future cash flow from operations, borrowings and financings.
Notably, Synovus has also been paying quarterly dividends, along with regular hikes. Since December 2016, the company has raised its dividend thrice. Its dividend was last hiked this March by 20% to 30 cents from 25 cents per share.
Synovus has rallied 2.2%, year to date, compared with the industry’s growth of 11.6%. Currently, the stock carries a Zacks Rank #3 (Hold).
With strong liquidity and balance-sheet position, we believe Synovus will continue to reward its shareholders, moving ahead. So, keeping this in mind, is the company worth considering? Let’s dig deeper into its financials and fundamental strengths.
Value Score: Synovus currently has a Value Score of B. The Value Score condenses all valuation metrics into one actionable score that helps investors steer clear of “value traps” and identify stocks that are truly trading at a discount.
Earnings Strength: Synovus has an expected earnings growth rate of 8%, for the coming three to five years. With its earnings momentum, the earnings growth rate is anticipated to be around 10.7% for the current year and 2.3% for 2020. Furthermore, the company recorded an average positive earnings surprise of 3.64%, over the trailing four quarters.
Revenue Growth: Synovus is focused on its organic growth strategy. Loans witnessed a CAGR of 5.3% for the last five years (2014-2018). In addition, net interest income (NII) witnessed a CAGR of 8.8% during the same time frame, partly driven by the acquisitions completed during this period. The increasing trend continued in first-quarter 2019 as well. Further, the company’s projected sales growth (F1/F0) of 35.5% (against nil industry average) indicates continued improvement in revenues.
Superior Return on Equity (ROE): Synovus’ ROE of 15.58%, as compared with the industry average of 9.93%, highlights the company’s commendable position over its peers.
Stocks to Consider
First Business Financial Services, Inc. (FBIZ - Free Report) has been witnessing upward estimate revisions, for the past 60 days. Moreover, this Zacks #1 (Strong Buy) Ranked stock has rallied more than 20%, year to date. You can see the complete list of today’s Zacks #1 Rank stocks here.
Franklin Resources, Inc. (BEN - Free Report) has been witnessing upward estimate revisions, for the past 60 days. Also, the company’s shares have gained nearly 10.8% year to date. At present, it carries a Zacks Rank of 2 (Buy).
1st Source Corporation (SRCE - Free Report) has been witnessing upward estimate revisions for the past 60 days. Additionally, the stock has jumped around 10.5% year to date. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>